(Q37771645)

22 August 2017

1 reference

title

Physical health management in psychiatric settings (English)

1 reference

22 August 2017

M De Hert

1

1 reference

22 August 2017

R van Winkel

2

1 reference

22 August 2017

A Silic

3

1 reference

22 August 2017

D Van Eyck

4

1 reference

22 August 2017

J Peuskens

5

1 reference

22 August 2017

language of work or name

English

0 references

publication date

1 June 2010

1 reference

22 August 2017

1 reference

22 August 2017

volume

25 Suppl 2

1 reference

22 August 2017

page(s)

S22-8

1 reference

From receptor pharmacology to improved outcomes: individualising the selection, dosing, and switching of antipsychotics

22 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0924-9338%2810%2971702-8

7 January 2021

Obesity as a risk factor for antipsychotic noncompliance.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-9338%2810%2971702-8

7 January 2021

Minimising metabolic and cardiovascular risk in schizophrenia: diabetes, obesity and dyslipidaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0924-9338%2810%2971702-8

7 January 2021

Causes of the excess mortality of schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0924-9338%2810%2971702-8

7 January 2021

Reversibility of antipsychotic treatment-related diabetes in patients with schizophrenia: a case series of switching to aripiprazole

1 reference

https://api.crossref.org/works/10.1016%2FS0924-9338%2810%2971702-8

7 January 2021

Health status of individuals with serious mental illness

1 reference

https://api.crossref.org/works/10.1016%2FS0924-9338%2810%2971702-8

7 January 2021

The impact of weight gain on quality of life among persons with schizophrenia.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-9338%2810%2971702-8

7 January 2021

Abnormal glucose metabolism in patients treated with antipsychotics

1 reference

https://api.crossref.org/works/10.1016%2FS0924-9338%2810%2971702-8

7 January 2021

Antipsychotic drugs and diabetes--an application of the Austin Bradford Hill criteria.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-9338%2810%2971702-8

7 January 2021

Belgian consensus on metabolic problems associated with atypical antipsychotics

1 reference

https://api.crossref.org/works/10.1016%2FS0924-9338%2810%2971702-8

7 January 2021

Foreword. Importance of physical health in patients with schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0924-9338%2810%2971702-8

7 January 2021

Metabolic monitoring for patients treated with antipsychotic medications

1 reference

https://api.crossref.org/works/10.1016%2FS0924-9338%2810%2971702-8

7 January 2021

Atypical antipsychotics and glucose dysregulation: a systematic review

1 reference

https://api.crossref.org/works/10.1016%2FS0924-9338%2810%2971702-8

7 January 2021

Mortality and causes of death in schizophrenia in Stockholm county, Sweden

1 reference

https://api.crossref.org/works/10.1016%2FS0924-9338%2810%2971702-8

7 January 2021

Consensus development conference on antipsychotic drugs and obesity and diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0924-9338%2810%2971702-8

7 January 2021

Do guidelines for severe mental illness promote physical health and well-being?

1 reference

https://api.crossref.org/works/10.1016%2FS0924-9338%2810%2971702-8

7 January 2021

Physical illness and schizophrenia: a review of the literature

1 reference

https://api.crossref.org/works/10.1016%2FS0924-9338%2810%2971702-8

7 January 2021

Body weight, image and self-esteem evaluation questionnaire: development and validation of a new scale.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-9338%2810%2971702-8

7 January 2021

Schizophrenia and increased risks of cardiovascular disease

1 reference

https://api.crossref.org/works/10.1016%2FS0924-9338%2810%2971702-8

7 January 2021

Clinicians' recognition of the metabolic adverse effects of antipsychotic medications.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-9338%2810%2971702-8

7 January 2021

Relationship of atypical antipsychotics with development of diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0924-9338%2810%2971702-8

7 January 2021

Atypical antipsychotic-induced diabetes mellitus: how strong is the evidence?

1 reference

https://api.crossref.org/works/10.1016%2FS0924-9338%2810%2971702-8

7 January 2021

Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiolog

1 reference

https://api.crossref.org/works/10.1016%2FS0924-9338%2810%2971702-8

7 January 2021

A case series: evaluation of the metabolic safety of aripiprazole

1 reference

https://api.crossref.org/works/10.1016%2FS0924-9338%2810%2971702-8

7 January 2021

Treatment with rosuvastatin for severe dyslipidemia in patients with schizophrenia and schizoaffective disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0924-9338%2810%2971702-8

7 January 2021

Body weight and self-esteem in patients with schizophrenia evaluated with B-WISE.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-9338%2810%2971702-8

7 January 2021

Metabolic abnormalities associated with second generation antipsychotics: fact or fiction? Development of guidelines for screening and monitoring

1 reference

https://api.crossref.org/works/10.1016%2FS0924-9338%2810%2971702-8

7 January 2021

Oral glucose tolerance tests in treated patients with schizophrenia. Data to support an adaptation of the proposed guidelines for monitoring of patients on second generation antipsychotics?

1 reference

https://api.crossref.org/works/10.1016%2FS0924-9338%2810%2971702-8

7 January 2021

Prevalence of diabetes, metabolic syndrome and metabolic abnormalities in schizophrenia over the course of the illness: a cross-sectional study

1 reference

https://api.crossref.org/works/10.1016%2FS0924-9338%2810%2971702-8

7 January 2021

Prevalence of the metabolic syndrome in patients with schizophrenia treated with antipsychotic medication

1 reference

https://api.crossref.org/works/10.1016%2FS0924-9338%2810%2971702-8

7 January 2021

The association of medical comorbidity in schizophrenia with poor physical and mental health.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-9338%2810%2971702-8

7 January 2021

Prevalence and predictors of lipid and glucose monitoring in commercially insured patients treated with second-generation antipsychotic agents

1 reference

https://api.crossref.org/works/10.1016%2FS0924-9338%2810%2971702-8

7 January 2021

Comorbid somatic illnesses in patients with severe mental disorders: clinical, policy, and research challenges.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-9338%2810%2971702-8

7 January 2021

Physical health in schizophrenia: a challenge for antipsychotic therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0924-9338%2810%2971702-8

7 January 2021

Physical health monitoring of patients with schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0924-9338%2810%2971702-8

7 January 2021

Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-9338%2810%2971702-8

7 January 2021

Adverse metabolic effects associated with atypical antipsychotics: literature review and clinical implications

1 reference

https://api.crossref.org/works/10.1016%2FS0924-9338%2810%2971702-8

7 January 2021

Self-reported body weight perception and dieting practices in community-dwelling patients with schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0924-9338%2810%2971702-8

7 January 2021

Excess mortality of schizophrenia. A meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0924-9338%2810%2971702-8

7 January 2021

The need for routine physical health care in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0924-9338%2810%2971702-8

7 January 2021

Medical co-morbidity risk factors and barriers to care for people with schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0924-9338%2810%2971702-8

7 January 2021

Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review

1 reference

https://api.crossref.org/works/10.1016%2FS0924-9338%2810%2971702-8

7 January 2021

The Atypical Antipsychotic Therapy and Metabolic Issues National Survey: practice patterns and knowledge of psychiatrists

1 reference

https://api.crossref.org/works/10.1016%2FS0924-9338%2810%2971702-8

7 January 2021

Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0924-9338%2810%2971702-8

7 January 2021

Body mass index and quality of life in community-dwelling patients with schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0924-9338%2810%2971702-8

7 January 2021

Screening for diabetes and other metabolic abnormalities in patients with schizophrenia and schizoaffective disorder: evaluation of incidence and screening methods.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-9338%2810%2971702-8

7 January 2021

Prevalence of diabetes and the metabolic syndrome in a sample of patients with bipolar disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0924-9338%2810%2971702-8

7 January 2021

Dysglycemia in a community sample of people treated for schizophrenia: the Diabetes in Schizophrenia in Central-South Ontario (DiSCO) study.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-9338%2810%2971702-8

7 January 2021

The risk of diabetes during olanzapine use compared with risperidone use: a retrospective database analysis.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-9338%2810%2971702-8

7 January 2021

10.1016/S0924-9338(10)71702-8

Identifiers

DOI

1 reference

22 August 2017

1 reference